Abundance Wealth Counselors Sells 174 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Abundance Wealth Counselors decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,712 shares of the biopharmaceutical company’s stock after selling 174 shares during the period. Gilead Sciences comprises approximately 0.6% of Abundance Wealth Counselors’ investment portfolio, making the stock its 27th biggest holding. Abundance Wealth Counselors’ holdings in Gilead Sciences were worth $2,560,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of GILD. Algert Global LLC purchased a new stake in Gilead Sciences during the second quarter valued at approximately $254,000. Quarry LP acquired a new position in shares of Gilead Sciences during the second quarter worth $43,000. Cetera Investment Advisers lifted its holdings in shares of Gilead Sciences by 1.8% during the 2nd quarter. Cetera Investment Advisers now owns 217,702 shares of the biopharmaceutical company’s stock valued at $14,937,000 after purchasing an additional 3,801 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $33,000. Finally, Sanctuary Advisors LLC purchased a new position in Gilead Sciences during the 2nd quarter worth $9,312,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.3 %

Shares of GILD stock opened at $97.20 on Friday. The stock has a 50 day simple moving average of $92.42 and a 200-day simple moving average of $85.77. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a market cap of $121.14 billion, a price-to-earnings ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GILD has been the subject of several recent analyst reports. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Oppenheimer boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Finally, Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $98.39.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 456,234 shares of company stock worth $42,130,461. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.